Witz Elected to PerkinElmer Board
Diagnostic solutions developer PerkinElmer Inc. has elected Pascale Witz to its board of directors.
“We would like to extend a warm welcome to Pascale as the newest member of our board,” said Robert Friel, chairman and CEO of PerkinElmer. “She brings a wide range of commercial healthcare and strategic management experience across the pharmaceutical, medical device and diagnostics industries, and I am confident that her leadership will be invaluable in helping drive the future direction of the company.”
Witz has more than 30 years of global experience, most recently serving as executive vice president of global diabetes and cardiovascular for Sanofi S.A. Prior to Sanofi, she held several leadership positions during her 17 years with GE Healthcare, including the role of president and CEO of its medical diagnostics division. She began her career in research before moving to a marketing role at Becton Dickinson France in 1991 and to GE Healthcare in 1996.
Witz currently serves on the board of directors of Horizon Pharma PLC, Regulus Therapeutics Inc., Fresenius Medical Care AG & Co. KGaA, Savencia SA, and French-American Foundation-France. Witz received her master’s degree in biochemistry from the Institut National des Sciences Appliquées de Lyon, France and an MBA in economics and marketing from INSEAD, Fontainebleau, France.
PerkinElmer is a developer of detection, imaging, informatics and service capabilities.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024